Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The contents of each vial were dissolved in the distilled water for injection, and the study drug (0.6 mg as KP-100) was administered intrathecally once per week a total of 5 times.”In the company’s words, NCT07722962 on ClinicalTrials.gov
- Tested for
- Acute Spinal Cord Injury (SCI)
- Main trialPhase 3
- “This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.”In the company’s words, NCT07722962 on ClinicalTrials.gov
- Other names
- Hepatocyte Growth Factor · HGF
Other drugs for Acute Spinal Cord Injury (SCI)
Coming up1
- 31 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 31 Dec 2028 | Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury | |
| Phase 3Unknown | 31 Dec 2022 | Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026